SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

09 Feb 2023 Evaluate
The sales moved up 30.85% to Rs. 34322.60 millions for the December 2022 quarter as compared to Rs. 26230.50 millions during the year-ago period.The Company has registered profit of Rs. 2988.20  millions for the quarter ended December 2022, a growth of 24.61%  over Rs. 2398.10 millions millions achieved in the corresponding quarter of last year.The company reported a good operating profit of 5519.50 millions compared to 3472.00 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 34322.60 26230.50 30.85 92448.40 83999.80 10.06 112871.40 158236.80 -28.67
Other Income 787.30 1312.90 -40.03 1733.00 2576.10 -32.73 6709.90 5898.60 13.75
PBIDT 5519.50 3472.00 58.97 11846.80 12240.60 -3.22 21443.90 47096.90 -54.47
Interest 389.60 35.40 1000.56 660.10 120.40 448.26 169.40 286.80 -40.93
PBDT 5129.90 3436.60 49.27 11186.70 12120.20 -7.70 20527.40 46810.10 -56.15
Depreciation 1085.00 1012.00 7.21 3203.50 3140.30 2.01 4152.60 4880.00 -14.91
PBT 4044.90 2424.60 66.83 7983.20 8979.90 -11.10 16374.80 41930.10 -60.95
TAX 1056.70 26.50 3887.55 2127.10 2454.30 -13.33 1827.70 10801.00 -83.08
Deferred Tax -84.80 -861.60 -90.16 -204.70 -1088.60 -81.20 -1969.30 367.60 -635.72
PAT 2988.20 2398.10 24.61 5856.10 6525.60 -10.26 14547.10 31129.10 -53.27
Equity 585.90 585.90 0.00 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 16.08 13.24 21.49 12.81 14.57 -12.06 19.00 29.76 -36.17

Aurobindo Pharma Share Price

1379.65 -6.00 (-0.43%)
20-Apr-2026 12:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.75
Dr. Reddys Lab 1236.90
Cipla 1236.85
Zydus Lifesciences 938.40
Lupin 2328.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×